

Appendix to slide34-84: The number of patients in each group and crude survival probabilities at 1, 5, and 10 years after transplantation.

Slide34. Survival after Transplants by Transplant Type, 1991-2021

	Years after the first transplantation	N	OS
Auto	At transplantation	38,746	
	1 year	29,564	84.3%
	5 years	14,158	62.8%
	10 years	5,579	51.7%
Allo	At transplantation	63,730	
	1 year	38,870	65.3%
	5 years	20,338	49.4%
	10 years	9,722	44.9%

Slide35. Survival after Transplants by Donor Type and Stem Cell Sources, 1991-2021

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	12,167	
	1 year	8,743	73.9%
	5 years	5,762	58.7%
	10 years	3,571	54.7%
Rel-PB	At transplantation	12,754	
	1 year	7,234	61.7%
	5 years	3,065	42.7%
	10 years	1,330	37.1%
UR-BM	At transplantation	21,846	
	1 year	13,775	67.1%
	5 years	7,639	51.4%
	10 years	3,437	46.6%
UR-PB	At transplantation	1,231	
	1 year	716	71.9%
	5 years	117	54.8%
	10 years	3	46.6%
UR-CB	At transplantation	15,732	
	1 year	8,398	58.3%
	5 years	3,752	44.0%
	10 years	1,381	39.9%

Slide36. Survival after Transplants for Leukemia, 1991-2021

	Years after the first transplantation	N	OS
AML	At transplantation	25,633	
	1 year	15,287	63.9%
	5 years	7,486	46.1%
	10 years	3,412	41.4%
ALL	At transplantation	13,410	
	1 year	9,022	71.4%
	5 years	4,728	52.4%
	10 years	2,337	48.0%
ATL	At transplantation	2,855	
	1 year	1,242	46.9%
	5 years	539	31.4%
	10 years	195	25.8%
CML	At transplantation	3,797	
	1 year	2,600	71.5%
	5 years	1,805	59.4%
	10 years	1,143	55.2%
MDS	At transplantation	7,076	
	1 year	4,287	65.8%
	5 years	2,027	49.1%
	10 years	819	42.4%

Slide37. Survival after Transplants for Malignant Lymphoma and MM/PCD, 1991-2021

	Years after the first transplantation	N	OS
NHL	At transplantation	22,179	
	1 year	14,703	73.2%
	5 years	7,579	57.8%
	10 years	3,102	50.3%
HL	At transplantation	1,750	
	1 year	1,384	87.1%
	5 years	691	70.2%
	10 years	241	63.3%
Other lymphoma / type missing	At transplantation	578	
	1 year	345	70.7%
	5 years	191	54.1%
	10 years	109	46.1%
MM/PCD	At transplantation	12,206	
	1 year	10,040	92.6%
	5 years	4,019	65.7%
	10 years	1,008	43.3%

Slide38. Survival after Autologous Transplants for Acute Leukemia, 1991-2021 <Autologous>

	Years after the first transplantation	N	OS
AML : Age ≤ 15	At transplantation	235	
	1 year	204	86.8%
	5 years	146	64.2%
	10 years	111	61.5%
AML : Age ≥ 16	At transplantation	1,511	
	1 year	1,181	83.6%
	5 years	725	67.8%
	10 years	364	64.0%
ALL : Age ≤ 15	At transplantation	393	
	1 year	320	81.4%
	5 years	230	59.7%
	10 years	155	55.4%
ALL : Age ≥ 16	At transplantation	349	
	1 year	210	61.4%
	5 years	92	31.7%
	10 years	55	27.0%

Slide39. Survival after Autologous Transplants for Malignant Lymphoma, 1991-2021 <Autologous>

	Years after the first transplantation	N	OS
NHL : Age ≤ 15	At transplantation	226	
	1 year	175	78.6%
	5 years	140	71.2%
	10 years	100	70.6%
NHL : Age ≥ 16	At transplantation	16,422	
	1 year	11,710	79.5%
	5 years	5,879	62.6%
	10 years	2,288	53.5%
HL : Age ≤ 15	At transplantation	38	
	1 year	33	86.8%
	5 years	16	74.4%
	10 years	8	74.4%
HL : Age ≥ 16	At transplantation	1,545	
	1 year	1,250	89.7%
	5 years	627	72.9%
	10 years	215	65.7%

Slide40. Survival after Autologous Transplants for MM/PCD, 1991-2021 <Autologous> (Age≥16)

	Years after the first transplantation	N	OS
MM / PCD	At transplantation	11,867	
	1 year	9,873	93.8%
	5 years	3,949	66.9%
	10 years	972	44.0%

Slide41. Survival after Allogeneic Transplants for AML, 2012-2021 <Allogeneic> (Age≤15)

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	157	
	1 year	110	73.3%
	5 years	41	56.7%
	10 years	1	55.2%
Rel-PB	At transplantation	98	
	1 year	66	74.8%
	5 years	15	48.5%
	10 years	0	.
UR-BM	At transplantation	149	
	1 year	110	81.7%
	5 years	47	65.5%
	10 years	1	63.2%
UR-CB	At transplantation	281	
	1 year	210	81.3%
	5 years	75	60.2%
	10 years	5	59.3%

Slide42. Survival after Allogeneic Transplants for AML, 2012-2021 <Allogeneic> (Age≥16)

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	593	
	1 year	410	74.0%
	5 years	163	54.9%
	10 years	8	50.8%
Rel-PB	At transplantation	2,777	
	1 year	1,580	64.3%
	5 years	424	43.3%
	10 years	11	36.5%
UR-BM	At transplantation	3,281	
	1 year	1,964	67.0%
	5 years	781	49.5%
	10 years	33	42.7%
UR-CB	At transplantation	4,246	
	1 year	2,201	58.9%
	5 years	636	42.4%
	10 years	22	35.0%

Slide43. Survival after Allogeneic Transplants for AML, 2012-2021 <HLA-identical Sibling> (Age≤15)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	61	
	1 year	51	91.2%
	5 years	13	68.3%
	10 years	0	.
Advanced risk	At transplantation	28	
	1 year	16	57.1%
	5 years	7	45.3%
	10 years	0	.

Slide44. Survival after Allogeneic Transplants for AML, 2012-2021 <HLA-identical Sibling> (Age≥16)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	1,265	
	1 year	958	83.6%
	5 years	337	62.1%
	10 years	14	53.7%
Advanced risk	At transplantation	638	
	1 year	276	47.2%
	5 years	74	27.2%
	10 years	2	24.7%

Slide45. Survival after Allogeneic Transplants for AML, 2012-2021 <UR-BM> (Age≤15)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	102	
	1 year	85	92.8%
	5 years	39	78.6%
	10 years	1	75.4%
Advanced risk	At transplantation	47	
	1 year	25	58.0%
	5 years	8	37.7%
	10 years	0	.

Slide46. Survival after Allogeneic Transplants for AML, 2012-2021 <UR-BM> (Age≥16)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	2,222	
	1 year	1,533	77.6%
	5 years	632	60.4%
	10 years	29	53.5%
Advanced risk	At transplantation	1,052	
	1 year	428	44.7%
	5 years	147	26.6%
	10 years	4	20.6%

Slide47. Survival after Allogeneic Transplants for AML, 2012-2021 <UR-CB> (Age≤15)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	185	
	1 year	164	95.5%
	5 years	63	77.6%
	10 years	4	77.6%
Advanced risk	At transplantation	94	
	1 year	44	52.9%
	5 years	11	25.2%
	10 years	1	25.2%

Slide48. Survival after Allogeneic Transplants for AML, 2012-2021 <UR-CB> (Age≥16)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	2,016	
	1 year	1,300	74.4%
	5 years	395	59.4%
	10 years	14	51.7%
Advanced risk	At transplantation	2,227	
	1 year	899	45.0%
	5 years	240	27.5%
	10 years	8	20.8%

Slide49. Survival after Allogeneic Transplants for ALL, 2012-2021 <Allogeneic> (Age≤15)

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	204	
	1 year	158	82.8%
	5 years	68	68.1%
	10 years	4	59.7%
Rel-PB	At transplantation	115	
	1 year	62	58.9%
	5 years	23	44.2%
	10 years	3	44.2%
UR-BM	At transplantation	237	
	1 year	185	87.2%
	5 years	78	72.2%
	10 years	2	69.8%
UR-CB	At transplantation	380	
	1 year	287	83.4%
	5 years	125	71.4%
	10 years	4	66.4%

Slide50. Survival after Allogeneic Transplants for ALL, 2012-2021 <Allogeneic> (Age≥16)

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	320	
	1 year	254	85.2%
	5 years	100	66.7%
	10 years	5	64.3%
Rel-PB	At transplantation	1,058	
	1 year	734	79.0%
	5 years	201	57.8%
	10 years	5	48.3%
UR-BM	At transplantation	1,604	
	1 year	1,125	78.9%
	5 years	446	61.3%
	10 years	15	58.9%
UR-CB	At transplantation	1,242	
	1 year	790	72.2%
	5 years	246	56.2%
	10 years	6	47.5%

Slide51. Survival after Allogeneic Transplants for ALL, 2012-2021 <HLA-identical Sibling> (Age≤15)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	59	
	1 year	51	94.8%
	5 years	30	88.6%
	10 years	3	85.2%
Advanced risk	At transplantation	62	
	1 year	43	76.3%
	5 years	12	51.7%
	10 years	0	

Slide52. Survival after Allogeneic Transplants for ALL, 2012-2021 <HLA-identical Sibling> (Age≥16)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	683	
	1 year	575	91.3%
	5 years	219	72.8%
	10 years	6	67.4%
Advanced risk	At transplantation	188	
	1 year	117	67.9%
	5 years	28	41.0%
	10 years	3	31.6%

Slide53. Survival after Allogeneic Transplants for ALL, 2012-2021 <UR-BM> (Age≤15)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	122	
	1 year	107	97.4%
	5 years	51	88.0%
	10 years	1	85.9%
Advanced risk	At transplantation	115	
	1 year	78	76.6%
	5 years	28	55.2%
	10 years	1	52.4%

Slide54. Survival after Allogeneic Transplants for ALL, 2012-2021 <UR-BM> (Age≥16)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	1,229	
	1 year	935	85.0%
	5 years	393	68.8%
	10 years	13	65.9%
Advanced risk	At transplantation	374	
	1 year	190	58.4%
	5 years	53	35.8%
	10 years	2	35.1%

Slide55. Survival after Allogeneic Transplants for ALL, 2012-2021 <UR-CB> (Age≤15)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	176	
	1 year	147	91.1%
	5 years	83	83.9%
	10 years	3	78.3%
Advanced risk	At transplantation	204	
	1 year	141	76.8%
	5 years	42	60.0%
	10 years	1	56.4%

Slide56. Survival after Allogeneic Transplants for ALL, 2012-2021 <UR-CB> (Age≥16)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	809	
	1 year	581	82.0%
	5 years	195	69.3%
	10 years	3	61.3%
Advanced risk	At transplantation	432	
	1 year	208	53.8%
	5 years	50	31.5%
	10 years	3	26.3%

Slide57. Survival after Allogeneic Transplants for CML, 2012-2021 <Allogeneic> (Age≤15)

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	14	
	1 year	11	78.6%
	5 years	9	78.6%
	10 years	0	.
Rel-PB	At transplantation	1	
	1 year	1	100.0%
	5 years	0	.
	10 years	0	.
UR-BM	At transplantation	13	
	1 year	10	84.6%
	5 years	7	76.2%
	10 years	0	.
UR-CB	At transplantation	7	
	1 year	7	100.0%
	5 years	2	100.0%
	10 years	0	.

Slide58. Survival after Allogeneic Transplants for CML, 2012-2021 <Allogeneic> (Age≥16)

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	36	
	1 year	29	91.0%
	5 years	12	79.4%
	10 years	0	.
Rel-PB	At transplantation	160	
	1 year	113	80.3%
	5 years	30	62.6%
	10 years	0	.
UR-BM	At transplantation	245	
	1 year	168	80.8%
	5 years	75	69.9%
	10 years	7	55.0%
UR-CB	At transplantation	182	
	1 year	114	74.7%
	5 years	56	67.5%
	10 years	1	54.3%

Slide59. Survival after Allogeneic Transplants for CML, 2012-2021 <HLA-identical Sibling> (Age≥16)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	47	
	1 year	36	95.3%
	5 years	14	83.6%
	10 years	0	.
Advanced risk	At transplantation	80	
	1 year	62	84.2%
	5 years	19	60.4%
	10 years	0	.

Slide60. Survival after Allogeneic Transplants for CML, 2012-2021 <UR-BM> (Age≥16)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	96	
	1 year	69	85.3%
	5 years	30	80.0%
	10 years	2	57.8%
Advanced risk	At transplantation	149	
	1 year	99	77.9%
	5 years	45	63.9%
	10 years	5	49.9%

Slide61. Survival after Allogeneic Transplants for CML, 2012-2021 <UR-CB> (Age≥16)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	58	
	1 year	40	85.3%
	5 years	13	79.7%
	10 years	0	.
Advanced risk	At transplantation	124	
	1 year	74	69.8%
	5 years	43	62.5%
	10 years	1	46.1%

Slide62. Survival after Allogeneic Transplants for MDS, 2012-2021 <Allogeneic> (Age≤15)

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	69	
	1 year	58	91.2%
	5 years	31	89.5%
	10 years	0	.
Rel-PB	At transplantation	13	
	1 year	10	83.3%
	5 years	3	74.1%
	10 years	0	.
UR-BM	At transplantation	118	
	1 year	94	92.0%
	5 years	40	80.3%
	10 years	1	80.3%
UR-CB	At transplantation	48	
	1 year	32	84.5%
	5 years	15	70.2%
	10 years	1	70.2%

Slide63. Survival after Allogeneic Transplants for MDS, 2012-2021 <Allogeneic> (Age≥16)

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	220	
	1 year	133	67.4%
	5 years	51	49.1%
	10 years	1	44.3%
Rel-PB	At transplantation	729	
	1 year	415	66.1%
	5 years	121	49.6%
	10 years	3	45.9%
UR-BM	At transplantation	1,545	
	1 year	940	67.1%
	5 years	314	46.9%
	10 years	15	37.6%
UR-CB	At transplantation	1,114	
	1 year	599	61.4%
	5 years	166	44.8%
	10 years	4	35.5%

Slide64. Survival after Allogeneic Transplants for MDS, 2012-2021 <HLA-identical Sibling> (Age≤15)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	45	
	1 year	39	91.1%
	5 years	21	91.1%
	10 years	0	.
Advanced risk	At transplantation	8	
	1 year	7	87.5%
	5 years	4	62.5%
	10 years	0	.

Slide65. Survival after Allogeneic Transplants for MDS, 2012-2021 <HLA-identical Sibling> (Age≥16)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	197	
	1 year	141	76.2%
	5 years	58	64.8%
	10 years	1	62.3%
Advanced risk	At transplantation	332	
	1 year	191	64.7%
	5 years	70	46.5%
	10 years	0	.

Slide66. Survival after Allogeneic Transplants for MDS, 2012-2021 <UR-BM> (Age≤15)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	80	
	1 year	69	97.4%
	5 years	34	87.8%
	10 years	1	87.8%
Advanced risk	At transplantation	29	
	1 year	21	89.7%
	5 years	6	72.5%
	10 years	0	.

Slide67. Survival after Allogeneic Transplants for MDS, 2012-2021 <UR-BM> (Age≥16)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	558	
	1 year	367	72.0%
	5 years	144	52.8%
	10 years	6	44.0%
Advanced risk	At transplantation	946	
	1 year	550	64.0%
	5 years	168	43.1%
	10 years	9	33.6%

Slide68. Survival after Allogeneic Transplants for MDS, 2012-2021 <UR-CB> (Age≤15)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	18	
	1 year	13	83.3%
	5 years	6	75.0%
	10 years	0	.
Advanced risk	At transplantation	24	
	1 year	16	85.0%
	5 years	8	63.8%
	10 years	1	63.8%

Slide69. Survival after Allogeneic Transplants for MDS, 2012-2021 <UR-CB> (Age≥16)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	344	
	1 year	201	66.4%
	5 years	56	51.0%
	10 years	0	.
Advanced risk	At transplantation	753	
	1 year	392	59.5%
	5 years	109	42.3%
	10 years	4	35.3%

Slide70. Survival after Allogeneic Transplants for NHL, 2012-2021 <Allogeneic> (Age≤15)

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	21	
	1 year	15	71.4%
	5 years	6	71.4%
	10 years	0	.
Rel-PB	At transplantation	19	
	1 year	12	63.2%
	5 years	4	44.9%
	10 years	0	.
UR-BM	At transplantation	31	
	1 year	21	72.7%
	5 years	8	62.6%
	10 years	0	.
UR-CB	At transplantation	46	
	1 year	31	73.2%
	5 years	13	73.2%
	10 years	0	.

Slide71. Survival after Allogeneic Transplants for NHL, 2012-2021 <Allogeneic> (Age≥16)

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	122	
	1 year	69	61.1%
	5 years	27	52.9%
	10 years	1	49.8%
Rel-PB	At transplantation	785	
	1 year	351	50.8%
	5 years	104	39.0%
	10 years	6	34.0%
UR-BM	At transplantation	606	
	1 year	355	64.6%
	5 years	165	50.1%
	10 years	7	49.0%
UR-CB	At transplantation	899	
	1 year	400	49.4%
	5 years	157	39.1%
	10 years	6	36.6%

Slide72. Survival after Allogeneic Transplants for NHL, 2012-2021 <HLA-identical Sibling> (Age≥16)

	Years after the first transplantation	N	OS
1CR	At transplantation	106	
	1 year	83	85.0%
	5 years	27	66.8%
	10 years	0	.
2CR	At transplantation	39	
	1 year	29	79.3%
	5 years	14	76.6%
	10 years	0	.
>=3CR	At transplantation	18	
	1 year	16	94.1%
	5 years	4	75.6%
	10 years	0	.
1PR	At transplantation	51	
	1 year	31	71.2%
	5 years	10	52.6%
	10 years	1	47.3%
2PR	At transplantation	52	
	1 year	29	62.5%
	5 years	16	55.2%
	10 years	1	55.2%
NIR	At transplantation	207	
	1 year	79	40.4%
	5 years	27	29.4%
	10 years	4	25.0%

Slide73. Survival after Allogeneic Transplants for NHL, 2012-2021 <UR-BM> (Age≤15)

	Years after the first transplantation	N	OS
1CR	At transplantation	5	
	1 year	5	100.0%
	5 years	1	100.0%
	10 years	0	.
2CR	At transplantation	5	
	1 year	3	60.0%
	5 years	2	60.0%
	10 years	0	.
>=3CR	At transplantation	1	
	1 year	0	.
	5 years	0	.
	10 years	0	.
1PR	At transplantation	4	
	1 year	2	66.7%
	5 years	1	33.3%
	10 years	0	.
2PR	At transplantation	1	
	1 year	0	.
	5 years	0	.
	10 years	0	.
NIR	At transplantation	15	
	1 year	11	78.6%
	5 years	4	65.5%
	10 years	0	.

Slide74. Survival after Allogeneic Transplants for NHL, 2012-2021 <UR-BM> (Age≥16)

	Years after the first transplantation	N	OS
1CR	At transplantation	143	
	1 year	102	81.2%
	5 years	48	65.5%
	10 years	0	.
2CR	At transplantation	74	
	1 year	56	82.0%
	5 years	29	66.1%
	10 years	1	58.8%
>=3CR	At transplantation	40	
	1 year	27	69.8%
	5 years	17	58.5%
	10 years	0	.
1PR	At transplantation	60	
	1 year	37	69.2%
	5 years	13	48.7%
	10 years	1	48.7%
2PR	At transplantation	65	
	1 year	39	66.1%
	5 years	19	51.3%
	10 years	0	.
NIR	At transplantation	224	
	1 year	94	45.7%
	5 years	39	33.6%
	10 years	4	32.7%

**Slide75. Survival after Allogeneic Transplants for NHL,
2012-2021 <UR-CB> (Age≤15)**

	Years after the first transplantation	N	OS
1CR	At transplantation	13	
	1 year	10	76.9%
	5 years	7	76.9%
	10 years	0	.
2CR	At transplantation	6	
	1 year	5	100.0%
	5 years	1	100.0%
	10 years	0	.
>=3CR	At transplantation	1	
	1 year	1	100.0%
	5 years	0	.
	10 years	0	.
2PR	At transplantation	7	
	1 year	5	83.3%
	5 years	0	.
	10 years	0	.
NIR	At transplantation	19	
	1 year	10	57.4%
	5 years	5	57.4%
	10 years	0	.

**Slide76. Survival after Allogeneic Transplants for NHL,
2012-2021 <UR-CB> (Age≥16)**

	Years after the first transplantation	N	OS
1CR	At transplantation	144	
	1 year	90	69.3%
	5 years	35	55.3%
	10 years	1	55.3%
2CR	At transplantation	85	
	1 year	40	60.9%
	5 years	22	53.4%
	10 years	1	48.1%
>=3CR	At transplantation	22	
	1 year	16	72.7%
	5 years	9	61.5%
	10 years	0	.
1PR	At transplantation	103	
	1 year	53	57.0%
	5 years	19	51.4%
	10 years	2	48.0%
2PR	At transplantation	86	
	1 year	36	48.1%
	5 years	11	39.7%
	10 years	0	.
NIR	At transplantation	458	
	1 year	164	38.4%
	5 years	61	27.9%
	10 years	2	25.4%

**Slide77. Survival after Autologous Transplants for MM /
PCD, 2012-2021 <Autologous> (Age≥16)**

	Years after the first transplantation	N	OS
MM / PCD	At transplantation	7,529	
	1 year	6,105	95.4%
	5 years	1,878	73.7%
	10 years	48	55.8%

**Slide78. Survival after Allogeneic Transplants for MM /
PCD, 2012-2021 <Allogeneic> (Age≥16)**

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	3	
	1 year	2	66.7%
	5 years	0	.
	10 years	0	.
Rel-PB	At transplantation	27	
	1 year	12	47.9%
	5 years	5	43.9%
	10 years	2	43.9%
UR-BM	At transplantation	24	
	1 year	13	54.2%
	5 years	4	28.6%
	10 years	0	.
UR-CB	At transplantation	17	
	1 year	4	26.5%
	5 years	1	13.2%
	10 years	0	.

Slide79. Survival after Autologous Transplants for MM / PCD, 2012-2021 <Autologous> (Age≥16)

	Years after the first transplantation	N	OS
CR / sCR	At transplantation	1,619	
	1 year	1,317	97.9%
	5 years	343	78.2%
	10 years	7	58.0%
VGPR	At transplantation	2,362	
	1 year	1,889	96.8%
	5 years	560	74.4%
	10 years	15	54.7%
PR	At transplantation	2,540	
	1 year	2,110	95.1%
	5 years	720	71.7%
	10 years	16	52.9%
SD	At transplantation	212	
	1 year	178	90.7%
	5 years	50	56.0%
	10 years	0	.
PD / Rel	At transplantation	157	
	1 year	90	66.1%
	5 years	17	32.0%
	10 years	1	26.0%

Slide80. Survival after Allogeneic Transplants for MM / PCD, 2012-2021 <Allogeneic> (Age≥16)

	Years after the first transplantation	N	OS
CR / sCR	At transplantation	16	
	1 year	10	67.7%
	5 years	2	67.7%
	10 years	0	.
VGPR	At transplantation	9	
	1 year	6	66.7%
	5 years	1	26.7%
	10 years	1	26.7%
PR	At transplantation	21	
	1 year	10	51.3%
	5 years	5	33.0%
	10 years	1	33.0%
SD	At transplantation	5	
	1 year	1	20.0%
	5 years	0	.
	10 years	0	.
PD / Rel	At transplantation	17	
	1 year	2	11.8%
	5 years	1	5.9%
	10 years	0	.

Slide81. Survival after Allogeneic Transplants for AA, 2012-2021 <Allogeneic> (Age≤15)

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	126	
	1 year	108	97.5%
	5 years	49	97.5%
	10 years	4	97.5%
Rel-PB	At transplantation	7	
	1 year	5	71.4%
	5 years	3	71.4%
	10 years	1	71.4%
UR-BM	At transplantation	135	
	1 year	113	96.1%
	5 years	53	95.1%
	10 years	2	95.1%
UR-CB	At transplantation	24	
	1 year	21	100.0%
	5 years	10	100.0%
	10 years	0	.

Slide82. Survival after Allogeneic Transplants for AA, 2012-2021 <Allogeneic> (Age≥16)

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	192	
	1 year	159	93.0%
	5 years	72	88.4%
	10 years	4	88.4%
Rel-PB	At transplantation	82	
	1 year	53	74.0%
	5 years	16	63.9%
	10 years	0	.
UR-BM	At transplantation	256	
	1 year	191	82.3%
	5 years	85	74.3%
	10 years	4	72.5%
UR-CB	At transplantation	130	
	1 year	83	69.7%
	5 years	34	67.8%
	10 years	0	.

**Slide83. Survival after Allogeneic Transplants for AA,
2012-2021 <Allogeneic> (Age≤15)**

	Years after the first transplantation	N	OS
HLA-identical Sibling	At transplantation	97	
	1 year	84	97.8%
	5 years	42	97.8%
	10 years	5	97.8%
UR-BM	At transplantation	135	
	1 year	113	96.1%
	5 years	53	95.1%
	10 years	2	95.1%
UR-CB	At transplantation	24	
	1 year	21	100.0%
	5 years	10	100.0%
	10 years	0	.

**Slide84. Survival after Allogeneic Transplants for AA,
2012-2021 <Allogeneic> (Age≥16)**

	Years after the first transplantation	N	OS
HLA-identical Sibling	At transplantation	200	
	1 year	166	89.3%
	5 years	75	83.9%
	10 years	4	83.9%
UR-BM	At transplantation	256	
	1 year	191	82.3%
	5 years	85	74.3%
	10 years	4	72.5%
UR-CB	At transplantation	130	
	1 year	83	69.7%
	5 years	34	67.8%
	10 years	0	.